Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy

AIDS and Behavior

Volumn 16, Issue 7, 2012, Pages 2082-2090

  Fatseas, Melina ^a,b   Denis, Cécile ^a,b,c   Serre, Fuschia ^a,b   Dubernet, Jacques ^a,b   Daulouède, Jean Pierre ^a,b,d   Auriacombe, Marc ^a,b,c,d  

^a CNRS   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Addiction Treatment Clinic Bizia   (France)

Author keywords

French harm reduction policy; HCV prevalence; HIV prevalence; Risk taking behaviors

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG ABUSE; EPIDEMIOLOGY; FEMALE; FRANCE; HARM REDUCTION; HEALTH BEHAVIOR; HEALTH CARE POLICY; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MALE; OPIATE ADDICTION; RISK FACTOR; SEXUAL BEHAVIOR; STATISTICS; SUBSTANCE ABUSE; TIME; VIROLOGY;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HARM REDUCTION; HEALTH BEHAVIOR; HEALTH POLICY; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; NEEDLE SHARING; OPIOID-RELATED DISORDERS; RISK FACTORS; RISK-TAKING; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; YOUNG ADULT;

EID: 84868488740     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-0054-4     Document Type: Article

References (46)

1. Yang X, Latkin C, Celentano D, Luo H. Prevalence and correlates of HIV risk behaviors among drug users in China. AIDS Behav. 2006;10(1):71-81
2. Zhao M, Du J, Lu GH, et al. HIV sexual risk behaviors among injection drug users in Shanghai. Drug Alcohol Depend. 2006; 82(Suppl 1):S43-7
3. Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend. 2006;82(Suppl 1):S35-8
4. Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001;27(1):71-8
5. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989;321(13):874-9
6. Koester S, Booth RE, Zhang Y. The prevalence of additional injection-related HIV risk behaviors among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(2): 202-7
7. Nicolosi A, Leite ML, Musicco M, Molinari S, Lazzarin A. Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study. Am J Epidemiol. 1992;135(3):225-33
8. Grund JP, Friedman SR, Stern LS, et al. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;42(5):691-703
9. Chitwood DD, Comerford M, Sanchez J. Prevalence and risk factors for HIV among sniffers, short-term injectors, and longterm injectors of heroin. J Psychoactive Drugs. 2003;35:445-53
10. Spittal P, Craib KJ, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002;66:894-9
11. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274(15):1226-31
12. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust. 1997;167(1):17-20
13. Beardsley M, Deren S, Tortu S, Goldstein MF, Ziek K, Hamid R. Trends in injection risk behaviors in a sample of New York City injection drug users: 1992-1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(3):283-9
14. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992 to 1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(5):505-11
15. Battjes RJ, Pickens RW, Brown LS Jr. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(1):90-6
16. Jauffret-Roustide M, Emmanuelli J, Quaglia M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data - the ANRS-Coquelicot Study. Subst Use Misuse. 2006;41(10-12):1603-21
17. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996- 2003. Addiction. 2005;100(11):1690-700
18. Ingold FR, Toussirt M. Les attitudes et les pratiques des usagers de drogues confrontés aux risques de contamination par le virus de l'immunodéficience humaine (VIH) et les virus des hépatites B et C. Bull Acad Natl Med. 1997;181(3):555-67. discussion 67-8
19. Valenciano M, Emmanuelli J, Lert F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction. 2001;96(4):597-606
20. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844-59
21. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010; 375:1014-28
22. Beck F, Guilbert P, Gautier A. Barometre santé 2005 Attitudes et comportements de santé. Saint-Denis: INPES; 2007
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Whashington: American Psychiatric association; 1994
24. Metzger D, Woody G, Druley P, et al. Psychiatric symptoms, high risk behaviors and HIV positivity among methadone patients. NIDA Res Monogr. 1990;105:490-1
25. Bertorelle V, Auriacombe M, Grabot D, et al. Evaluation quantitative des pratiques de partage de materiel a risque de contamination infectieuse virale chez les usagers d'opiaces par voie intraveineuse faisant une demande de soins - utilisation de l'autoquestionnaire RAB. Encephale. 2000;26(3):3-7
26. Brisseau S, Auriacombe M, Franques P, Daulouede JP, Tignol J. L'Addiction severity index. Le Courrier des Addictions. 1999;1: 200-3
27. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index: historical critique and normative data. J Subst Abuse Treat. 1992;9:199-213
28. Bergeron J, Landry M, Brochu S, Guyon L. Les études psychométriques autour de l'ASI/IGT. In: Guyon L, Landry M, Brochu S, Bergeron J, editors. L'évaluation des clienteles alcooliques et toxicomanes. Les Presses de l'Université Laval; 1998. p. 31-46
29. Metzger D, Woody G, Navaline H. The risk assessment battery: validity and reliability. Presented in the 6th annual meeting of the National Cooperative Vaccine Development Group for AIDS; 1993
30. Palle C, Chabane C, Lemieux C, Prisse N. Les centres de soins spécialisés aux toxicomanes en 2004. Exploitation des rapports d'activité-type des CSST. Paris: OFDT; Décembre 2006
31. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997 Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(4): 358-64
32. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Cohorte Aquitaine, Systeme d'information GECSADM12. Rapport d'activité no 16. Bordeaux; Décembre 2004
33. Lewden C, Bonnet F, Bevilacqua S, et al. Causes de deces chez les usagers de drogues francais infectes parle VIH, 1995-2002. Ann Med Interne (Paris). 2002;153(7 Suppl):2S4-10
34. Institut de veille sanitaire. Bullletin épidémiologique hebdomadaire. L'infection a VIH/sida en France et en Europe. Saint- Maurice, France; 2007
35. Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95(8):1439-44
36. Institut de veille sanitaire. Systeme d'information sur l'accessibilité au matériel officinal d'injection stérile et a la substitution (SIAMOIS), Paris; 2006
37. McCoy CB, Metsch LR, Comerford M, Zhao W, Coltes AJ, Messiah SE. Trends of HIV risk behaviors in a cohort of injecting drug users and their sex partners in Miami, Florida, 1988-1998. AIDS Behav. 2005;9(2):187-99
38. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645-53
39. Holtzman D, Barry V, Ouellet LJ, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med. 2009;49(1):68-73
40. Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS. 2005;19(Suppl 3):S20-5
41. Sarkar K, Mitra S, Bal B, Chakraborty S, Bhattacharya SK. Rapid spread of hepatitis C and needle exchange programm in Kolkata, India. Lancet. 2003;361(9365):1301-2
42. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology. 1992; 16(5):1109-14
43. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-6
44. McMahon JM, Simm M, Milano D, Clatts M. Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob. 2004;3:6
45. McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003;35(4):455-60
46. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007; 9(5):358-64.